Open AccessRuxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS
Author(s) -
Shuna Luo,
Xiaofei Xu,
Xingg Ye,
Xiaoqiong Zhu,
Cai Wu,
Dan Chen,
Jingxia Jin,
Yan Zheng,
Minxue Zheng,
Jian Huang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s272207
Subject(s) - myeloproliferative neoplasm , ruxolitinib , decitabine , medicine , kras , myelofibrosis , myelodysplastic syndromes , international prognostic scoring system , azacitidine , oncology , cancer research , cancer , bone marrow , gene , biology , gene expression , colorectal cancer , dna methylation , biochemistry
Myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U) is a subtype of MDS/MPN that exhibits a combination of the features of both MDS and MPN. To date, no curative treatment is available for MDS/MPN-U; however, previous studies have suggested a potential survival advantage for ruxolitinib and hypomethylating agents. We reported a case of a JAK2 -negative but KRAS -positive MDS/MPN-U patient treated with ruxolitinib plus decitabine. After treatment, the patient's clinical symptoms were moderated, and the size of the spleen and the peripheral blood cell counts were reduced. These effects might be due to the regimen's ability to reduce STAT5 activation and upregulate microRNA-181c to downregulate the variant allele frequency (VAF) of KRAS .